Previous studies have shown that TKIs are particularly effective in patients with activating mutations in the tyrosine kinase domain of the EGFR gene, underscoring TKIs as a promising therapeutic avenue for patients with advanced EGFR-mutated NSCLC (5). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.